Abstract
The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative (PPMI) is an observational study to comprehensively evaluate Parkinson’s disease (PD) patients using imaging, biologic sampling, clinical and behavioural assessments to identify biomarkers of PD progression. As part of this study, we obtained 4,756 whole blood samples from 1,570 subjects at baseline, 0.5, 1, 2, and 3 years from enrollment in the study. We isolated RNA and performed whole transcriptome sequencing in this longitudinal cohort. Here, we describe and quantify technical variability associated with this dataset through the use of pooled reference samples, including plate distribution, RNA quality, and outliers. This large, uniformly processed dataset is available to researchers at https://www.ppmi-info.org.
Competing Interest Statement
BC, SM, AR are employees of the Michael J. Fox Foundation (MJFF). EH, DC, IV, ER, AT, KVKJ are funded by MJFF. The authors declare that the employment or funding from MJFF in no way affected the design, results or interpretations presented.
Clinical Protocols
Funding Statement
This research was supported and funded by the Michael J Fox Foundation for Parkinsons Research (MJFF). Many MJFF staff assisted in getting data harmonized and transferred. This research was supported in part by the Intramural Research Program of the National Institute of Health (NIH), National Institute on Aging (NIA). BC, SM, AR are employees of the Michael J. Fox Foundation (MJFF). EH, DC, IV, ER, AT, KVKJ are funded by MJFF. The authors declare that the employment or funding from MJFF in no way affected the design, results or interpretations presented.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants were enrolled at 33 clinical sites across the US (21), Europe (10), Israel (1), and Australia (1). This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines after approval of the local ethics committees of the participating sites. The study was approved by the Research Subjects Review Board at the University of Rochester, and by the institutional review board at each site. Full inclusion and exclusion criteria are listed at clinicaltrials.gov (Identifier: NCT01141023) and at https://ppmi-info.org.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available in a public (institutional, general or subject specific) repository that does not issue datasets with DOIs (non-mandated deposition). The sequencing data that support the findings of this study are available from Accelerating Medical Partnerships: Parkinsons Disease (AMP PD; https://amp-pd.org/). These are the requirements for downloading from AMP PD: 1. Personal and institutional/company details; 2. Description of intended data use e.g. proposed analyses; 3. Institutional signature on the AMP PD Data Use Agreement (for researchers requesting access to individual-level, omics data). All code used for data analysis is available at github: https://github.com/tgen/ppmi-qc-wt-paper
